Sentinel Dosing-Time for a Risk-Based Approach?

Autor: Bonate PL, Rogge M, Gries JM, Prokopienko AJ, Pai SM

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2024 Nov 24. Date of Electronic Publication: 2024 Nov 24.

Blueprint for antibody biologics developability.

Autor: Mieczkowski C; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Zhang X; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Lee D; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Nguyen K; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Lv W; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Wang Y; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Zhang Y; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Way J; Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA., Gries JM; President, Discovery Research, Hengenix Biotech, Inc, Milpitas, CA, USA.

Publikováno v: MAbs [MAbs] 2023 Jan-Dec; Vol. 15 (1), pp. 2185924.

Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA.

Autor: Pai SM, Othman AA, Rusch L, Masters JC, Greene D, Rogge M, Gries JM, Clementi W, Kumar P, Younis I, Salem AH, Gaynes BI, Pastino G, Derendorf H

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2021 Mar; Vol. 61 (3), pp. 277-279. Date of Electronic Publication: 2021 Jan 27.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.